Perivascular epithelioid cell neoplasm

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Nov 2021

Fyarro: FDA approved

treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa)

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Perivascular epithelioid cell neoplasm.
Check the disease page for updates →

Approved Treatments

4 FDA-approved

Fyarro

(sirolimus protein-bound particles for injectable suspension (albumin-bound))Orphan drug

Aadi Bioscience, Inc.

mTOR Inhibitor Immunosuppressant [EPC]

12.1 Mechanism of Action Sirolimus in FYARRO is an inhibitor of mechanistic target of rapamycin kinase (mTOR, previously known as mammalian target of ...

Approved Nov 2021FDA label ↗

Urea 39.5% With 2% Salicylic Acid

(UREA, SALICYLIC ACID)Orphan drugstandard

PureTek Corporation

FDA label ↗

Dermacure

(UREA 41%)Orphan drugstandard

Oncora Pharma, LLC

FDA label ↗

Urea Cream 40 Percent

(UREA)Orphan drugstandard

Method Pharmaceuticals, LLC

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Perivascular epithelioid cell neoplasm.
Search all trials →
Search clinical trials for Perivascular epithelioid cell neoplasm

Recent News & Research

2 articles
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncMar 20, 2026

Alternative Lengthening of Telomeres in Malignant Perivascular Epithelioid Cell Neoplasms: Correlation With Molecular Features Including ATRX Gene Mutation Status.

A subset of perivascular epithelioid cell neoplasms (PEComas) is histologically malignant and at high risk for metastasis, and there is limited literature available on the genetic features of these le...

Read ↗
Urologic oncologyJan 18, 2026

Renal epithelioid angiomyolipoma: A multi-institutional, international cohort study with emphasis on clinicopathologic prognostic indicators.

Renal angiomyolipoma (AML) is a benign perivascular epithelioid cell neoplasm that is often associated with tuberous sclerosis complex (TSC). Epithelioid AML (eAML), a very rare and potentially malign...

Read ↗

Browse all Perivascular epithelioid cell neoplasm news →

Specialist Network

Top 6 by expertise

View all Perivascular epithelioid cell neoplasm specialists →

Quick Actions